Coronary Artery Calcification in Type 2 Diabetes Mellitus (USCAC Study)
Launched by UNIVERSITY OF SOUTH CHINA · May 11, 2021
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
The USCAC Study is a clinical trial that aims to understand the issue of coronary artery calcification (CAC) in people with type 2 diabetes. CAC is a condition where calcium builds up in the arteries, which can lead to serious heart problems and increase the risk of death. This study will look at how common CAC is among type 2 diabetes patients in Hunan province, how statin medications may affect it, and whether a specific molecule called miR-32 could help with early diagnosis. The researchers hope that their findings will lead to better prevention and treatment strategies for patients with both diabetes and coronary artery calcification.
To participate in this study, individuals need to be at least 18 years old and diagnosed with type 2 diabetes. They must also be able to undergo a specific type of heart scan. However, people who have had certain heart surgeries, have severe health issues, or are pregnant cannot join the study. Participants will be monitored closely throughout the trial, and their experiences may contribute valuable information to improve heart health in people living with diabetes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years old
- • Type 2 diabetes is diagnosed according to WHO diagnostic criteria
- • Low dose prospectively triggered sequential dual-source CT coronary angiography can be performed at baseline investigation
- • Those subjects are able to understand the purpose and procedure of this study and sign the informed consent voluntarily
- Exclusion Criteria:
- • Those have received coronary artery stenting or coronary artery bypass grafting
- • Those with severe lung (respiratory failure), liver (ALT or AST 3 times normal value or bilirubin increase), renal dysfunction\[GFR \< 45ml/(min.1.73m2) or dialysis patients
- • Malignant tumor
- • Mental illness or mental retardation
- • Pregnant or lactating women or those with fertility planning
- • Concomitant diseases (hyperparathyroidism, sarcoidosis, amyloidosis) affecting calcium balance and soft tissue calcification
- • Contraindications of contrast agents
- • Based on the judgment of the researcher, the compliance is poor and the study could not be completed according to the requirements
About University Of South China
The University of South China is a leading academic institution dedicated to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university fosters a dynamic environment for conducting clinical trials that aim to enhance patient care and improve health outcomes. The institution is committed to adhering to the highest ethical standards and regulatory requirements while engaging in groundbreaking studies across various medical fields. By leveraging its robust network of healthcare professionals and researchers, the University of South China strives to contribute significantly to the global body of medical knowledge and the development of effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hengyang, , China
Patients applied
Trial Officials
Liu Jianghua, PhD
Study Chair
The First Affiliated Hospital of University of South China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials